Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model.

ABSTRACT: Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10⁶ HGF-loaded microspheres (MS+HGF, n = 7), 5 × 10⁶ placebo microspheres (MS, n = 7), or saline (SAL, n = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma c

SUBMITTER: Blanco-Blazquez V 

PROVIDER: S-EPMC9960949 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature